GDP in the US: Additional FDA Guidances on DSCSA

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
In the last few days and weeks, the U.S. Food and Drug Administration (FDA) has published several guidance documents related to the requirements under the Drug Supply Chain Security Act (DSCSA). Under the DSCSA, trading partners (manufacturers, repackagers, wholesale distributors, and dispensers) are subject to certain requirements for enhanced drug distribution security.
Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act - Compliance Policies
This document published on 28 August 2023 describes the FDA’s compliance policies regarding enforcement of requirements for the interoperable, electronic, package level product tracing under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The guidance is for immediate implementation.
The guidance is available for download on the FDA homepage. Please also see our summary.
Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act
According to the FDA, this guidance published on 30 August 2023 "is intended to assist supply chain stakeholders, particularly trading partners, with requirements for enhanced drug distribution security at the package level under section 582 of the Federal Food, Drug, and Cosmetic Act (FD&C Act)."
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product - Compliance Policies
Revision 1 of the document was published on 01 September 2023. The authority writes that "this revised guidance explains that FDA intends to extend for an additional year (from November 27, 2023, to November 27, 2024), the enforcement policies described in the guidance entitled “Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product-Compliance Policies,” published in the Federal Register on October 23, 2020 (the 2020 Compliance Policies)."
DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry
This document published on 06 September 2023 finalizes the revised draft guidance of the same title. It "identifies the standards necessary to facilitate adoption of secure, interoperable, electronic data exchange among the pharmaceutical distribution supply chain, and clarifies the trading partners, products, and transactions subject to such standards."
Related GMP News
10.06.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
10.06.2025New MHRA Blog Post: Supplying Medicines to Ships, Aircraft and Oil Platforms
10.06.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 3
10.06.2025Meet the GDPA Board Members at the GDP Forum in Barcelona
10.06.2025Swissmedic Technical Interpretation: What Counts as a Major Change in GDP?
10.06.2025MHRA informes about Validity Date of UK issued GDP Certificates